Navigation Links
Anthera Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application Covering A-002 Plus Statin Compositions
Date:9/8/2011

b is a potent oral inhibitor of a number of pro-inflammatory enzymes collectively known as secretory phospholipase A2 (sPLA2). Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including ACS and acute chest syndrome, as well as chronic diseases, such as stable coronary artery disease (CAD). In Anthera's FRANCIS Phase 2 clinical study in ACS patients, treatment with varespladib improved independent markers of cardiovascular risk including C-reactive protein, IL-6, LDL-C and varespladib's target enzyme, sPLA2. Recent analysis of data from diabetic patients in the same Phase 2 study demonstrated treatment with varespladib was associated with early and statistically significant reductions in these prognostic inflammatory markers of cardiovascular risk. VISTA-16 is an event driven clinical study evaluating the use of varespladib methyl in combination with Lipitor (atorvastatin calcium) to reduce secondary Major Adverse Cardiovascular Events in patients who have recently experienced an Acute Coronary Syndrome. In February 2010, Anthera received a SPA from the U.S. FDA for the VISTA-16 Phase 3 study for the use of varespladib in treating high-risk ACS patients.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has three late stage clinical products: varespladib methyl (A-002), A-001 and blisibimod (A-623). Varespladib methyl (A-002) and A-001 are designed to inhibit a novel enzyme target known as secretory phospholipase A2 (sPLA2). Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. Blisibimod targets elevated levels of B-lymphocyte stimulator (BAFF) whic
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operational Update
2. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
3. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
4. Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update
5. Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
6. Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
7. Anthera Pharmaceuticals Names Lawrence Rosania as Vice President of Global Regulatory Affairs and Compliance
8. Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors
9. Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Antheras Investigational Novel Peptibody Agent
10. Anthera Announces Update Call Regarding Vial Problems
11. Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 Boston Scientific Corporation (NYSE: ... Credit Suisse Annual Healthcare Conference on Tuesday, November 11, ... Dan Brennan , executive vice president and chief financial ... at approximately 8:00 a.m. PT followed by a question ... the presentation and question and answer session will be ...
(Date:10/30/2014)... , Oct. 30, 2014 CVS Health (NYSE: ... new clinical affiliations with three leading regional health systems to ... The collaborating health systems include Baptist Health System in ... which include Commonwealth Health in Pennsylvania , ... Arizona , and Tennova Healthcare in Tennessee ...
(Date:10/30/2014)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ... clinical grade hypothermic storage and cryopreservation ... for cells and tissues, today announced today that ... released on Thursday, November 6, 2014, and that the ... at 1:30 p.m. PST that afternoon. Management will provide ...
Breaking Medicine Technology:Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2
(Date:10/30/2014)... October 30, 2014 Don Allred Insurance, ... health insurance plans for North Carolina residents, is excited ... in Burlington’s Holly Hill Mall. The new branch has ... already helping customers through all facets of the insurance ... Allred Insurance spokesman Scott Allred couldn’t be happier with ...
(Date:10/30/2014)... 30, 2014 Five months after their ... Street LLC announces new branding and a website to ... . After David Mepham’s promotion to name partner earlier ... website to include Mepham’s name and better reflect their ... mediation firm, the decision to implement new branding reflects ...
(Date:10/30/2014)... N.C. (PRWEB) October 30, 2014 Paramount ... health care, is increasing efforts to help people save ... expenses continue to increase for prescription drugs in the ... valuable savings and resources to bridge the relationship between ... One of the biggest challenges people face today with ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. 29, ... prostate cancer who also have certain heart problems may increase ... study suggests. , , The therapy in question is called androgen ... levels of male hormones to prevent the growth of cancer ... this hormone therapy was linked to triple the risk of ...
(Date:10/30/2014)... By Dennis Thompson ... -- The Ebola outbreak in Liberia -- one of three ... slowing, World Health Organization officials said Wednesday. Dr. Bruce ... in the number of burials in Liberia and no increase ... the global push to tame the epidemic may be making ...
Breaking Medicine News(10 mins):Health News:Allred Insurance Satellite Office Grand Opening 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3
... , PORTLAND, Ore., July 29 While Congress debates ... its work to engage consumers to transform health care from the ... System - Engaging Consumers to Create Value-Driven Health Care," designed for ... and from Healthcare Marketing Report,s Annual Healthcare Advertising Awards. An interactive ...
... Death risk only 0.3 percent, chances of serious complications ... For those considering bariatric surgery to combat significant obesity, ... be much lower than what has previously been reported. ... surgery and laparoscopic adjustable gastric banding (lap-band surgery), found ...
... , , ST. LOUIS, July 29 ... quarter net income from continuing operations of $192.0 million, or $0.74 ... related to the previously announced acquisition of WellPoint,s pharmacy benefit management ... $0.76 for the same period last year. These earnings for the ...
... , , , SAN DIEGO, ... medical device company focused on developing products for minimally disruptive surgical ... of Finance and Investor Relations, is scheduled to present at the ... Hotel in New York, New York, on Wednesday, August 5, 2009, ...
... , COLUMBUS, Ohio, July 29 Roxane ... Drug Application (ANDA) for Risperidone Oral Solution, 1mg/mL by the ... 30mL bottles for immediate shipment to wholesalers and pharmacies nationwide. ... 1mg/mL are AA rated to RISPERDAL(R) (risperidone) oral solution. Annual ...
... , WASHINGTON, July 29 Three of the ... by supporting the Obama health-care plan, which would foster a ... sex education, euthanasia and eugenics. , , ... , , Catholic Charities USA, the Society ...
Cached Medicine News:Health News:Regence Wins Awards for Consumer Appeal to Transform Health Care 2Health News:Study Finds Weight-Loss Surgery Safer Than Thought 2Health News:Study Finds Weight-Loss Surgery Safer Than Thought 3Health News:Express Scripts Reports Strong Second Quarter Earnings 2Health News:Express Scripts Reports Strong Second Quarter Earnings 3Health News:Express Scripts Reports Strong Second Quarter Earnings 4Health News:Express Scripts Reports Strong Second Quarter Earnings 5Health News:Express Scripts Reports Strong Second Quarter Earnings 6Health News:Express Scripts Reports Strong Second Quarter Earnings 7Health News:Express Scripts Reports Strong Second Quarter Earnings 8Health News:Express Scripts Reports Strong Second Quarter Earnings 9Health News:Express Scripts Reports Strong Second Quarter Earnings 10Health News:Express Scripts Reports Strong Second Quarter Earnings 11Health News:Express Scripts Reports Strong Second Quarter Earnings 12Health News:Express Scripts Reports Strong Second Quarter Earnings 13Health News:Express Scripts Reports Strong Second Quarter Earnings 14Health News:NuVasive to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference 2Health News:NuVasive to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference 3Health News:Roxane Laboratories, Inc. Announces the Launch of Risperidone Oral Solution 1mg/mL 2Health News:Catholic Charities, Vincent De Paul Society Supporting Abortion-Providing Healthcare Plan, Says ALL 2
... 2 adjustable belt buckle. You adjust once and ... off your shoulders. And now theres our Lady ... anatomy. ,For additional back support try one of ... on the vertebrae and help lift the apron ...
The Easy Wrap Apron is now available with an attached Thyroid Collar. The Thyroid Collar is held on with velcro so it adjusts to fully protect the neck. This Apron with Collar is available in 5mm lea...
The major innovation in posterior stabilized (PS) knee design. Improve patellofemoral kinematics. Reduce wear rate potential. Increase resistance to posterior tibial dislocation. Achieve at least 120...
StelKast's Proven™ Knee System is a long term high quality solution based on a clinically proven and successful design....
Medicine Products: